The Ministry of Health of the Republic of Uzbekistan The Pharmaceutical Industry Development Agency
Ру O`z Ўз En

Uzbek Specialists Discussed with Chinese Colleagues the Conduct of Phase 3 Clinical Trial of Vaccine for COVID-19 in Our Country

An online meeting of representatives of the healthcare system of Uzbekistan and China took place this August 11. The meeting focused on establishing cooperation in developing opportunities for conducting the third phase of clinical trials of the Chinese vaccine for SARS-CoV2 coronavirus in Uzbekistan.

Leading specialists of the Pharmaceutical Industry Development Agency, the management and experts of the Tashkent Research Institute of Vaccines and Whey, the Agency for Sanitary and Epidemiological Welfare, as well as representatives of the Embassy of Uzbekistan in China attended the meeting.

The Chinese side was represented by the management of the Beijing International Trade and Economic Company and the Sinopharm Corporation.

During the meeting, the Chinese side said that the Wuhan Institute of Biological Products and the Beijing Institute of Biologic Products - part of China National Biotech Group under the Ministry of Health of China, are currently in the last, third phase of clinical trials of a vaccine against coronavirus infection COVID-19.

The first and second phases of clinical trials of the medication were conducted at the end of April with the participation of more than 1,100 volunteers. Clinical trials have shown the vaccine to be safe ‘without a serious adverse reaction’. All participants in the trials had a high level of antibody production.

In June, China’s National Medical Products Administration authorized Wuhan researchers to move to the phase 3. The Chinese side also noted that at the moment about 30 governments are interested in conducting the third phase of clinical trials in their countries, and currently the Chinese side is closely cooperating with the United Arab Emirates in the framework of the third phase of clinical trials.

At the online meeting, the Chinese side proposed to consider the possibilities of conducting the third phase of clinical trials in Uzbekistan, as well as to send them a letter about the needs of the population of Uzbekistan for a vaccine, for further discussion of the purchase of vaccines by the Uzbek side.

In turn, the Uzbek side proposed the creation of a joint Uzbek-Chinese expert group in order to study the results of clinical trials and discuss details of further cooperation.

Press Office, the Pharmaceutical Industry Development Agency

 

 

Click on the button below to listen to the text Powered by GSpeech